TransCode Therapeutics Inc. Common Stock (RNAZ)

About RNAZ

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in v…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

12

Website

www.transcodetherapeutics.com

Fundamentals

1-day range

$3.21$3.7

Market cap

$4.52M

P/E (trailing)

—

P/E (forward)

-5.47

EPS (trailing)

$-3.71

Dividend yield

—

Beta

1.24

Avg. volume

63.2K

TransCode Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• RNAZ

  TransCode Therapeutics Inc. Common Stock

  $2.18

  ▼ 4.39%
  Market cap $4.52MP/E —
  $3.21$20.99
• DRMA

  Dermata Therapeutics Inc. Common Stock

  $1.49

  ▲ 1.71%
  Market cap $4.46MP/E —
• REVB

  Revelation Biosciences Inc. Common Stock

  $1.05

  ▲ 1.94%
  Market cap $4.38MP/E 0.04
  $0.875$11.6
• PPCB

  Propanc Biopharma Inc. Common Stock

  $1.4

  ▼ 37.22%
  Market cap $4.76MP/E —
  $0.95$85.5
• JUNS

  Jupiter Neurosciences Inc. Common Stock

  $4.59

  ▼ 6.13%
  Market cap $4.24MP/E —
  $4.1$138
• INM

  InMed Pharmaceuticals Inc. Common Shares

  $1.43

  ▼ 0.35%
  Market cap $4.01MP/E —
  $0.575$2.5
• ERNA

  Ernexa Therapeutics Inc. Common Stock

  $4.57

  ▼ 4.99%
  Market cap $5.09MP/E —
  $3.18$71.5

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

27.9K

Total value held

$240.0K

Institutional holders

7